Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
| Autor: | Anna Soria, Mariona Calvo, Meritxell Casas, Zara Vidales, Sergio Muñoz-Martínez, Victor Sapena, Marc Puigvehi, Lidia Canillas, Raquel Guardeño, Adolfo Gallego, Beatriz Mínguez, Diana Horta, Ariadna Clos, Silvia Montoliu, Mercè Roget, Maria Reig, Mercedes Vergara |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Soria A, Casas M] Department of Digestive Diseases, Liver Unit, Parc Taulí University Hospital, Investigation and Innovation Institute Parc Taulí I3PT, Universitat Autònoma of Barcelona, Bellaterra, Spain. [Calvo M, Vidales Z] Medical Oncology Department, Catalan Institute of Oncology, Hospitalet, Barcelona, Spain. [Muñoz-Martínez S] Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Clinical Insitute of Digestive and Metabolic Diseases (ICMDiM), Clinic Hospital, Barcelona University, Barcelona, Spain. Biomedical Research Center in Digestive and Liver Diseases Network (CIBERehd), Instituto Carlos III, Madrid, Spain. [Sapena V] Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Clinical Insitute of Digestive and Metabolic Diseases (ICMDiM), Clinic Hospital, Barcelona University, Barcelona, Spain. Medical Statistics Core Facility, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic Barcelona, Barcelona, Spain. Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma of Barcelona, Bellaterra, Spain. [Mínguez B] Biomedical Research Center in Digestive and Liver Diseases Network (CIBERehd), Instituto Carlos III, Madrid, Spain. Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma of Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, [Soria A, Casas M] Department of Digestive Diseases, Liver Unit, Parc Taulí University Hospital, Investigation and Innovation Institute Parc Taulí I3PT, Universitat Autònoma of Barcelona, Sabadell, Spain. [Calvo M, Vidales Z] Medical Oncology Department, Catalan Institute of Oncology, Hospitalet, Barcelona, Spain. [Muñoz-Martínez S] Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Clinical Insitute of Digestive and Metabolic Diseases (ICMDiM), Clinic Hospital, Barcelona University, Barcelona, Spain. Biomedical Research Center in Digestive and Liver Diseases Network (CIBERehd), Instituto Carlos III, Madrid, Spain. [Sapena V] Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Clinical Insitute of Digestive and Metabolic Diseases (ICMDiM), Clinic Hospital, Barcelona University, Barcelona, Spain. Medical Statistics Core Facility, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic Barcelona, Barcelona, Spain. Liver Unit, University Hospital Vall d'Hebron, Liver Diseases Research Group, Vall d'Hebron Institut of Research (VHIR), Universitat Autònoma of Barcelona, Barcelona, Spain. [Roget M] Servei de Malalties Digestives, Unitat Hepàtica, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain, Consorci Sanitari de Terrassa |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Cancer Research
Digestive System Diseases::Digestive System Diseases::Liver Diseases::Liver Neoplasms::Carcinoma Hepatocellular [DISEASES] Hepatocellular carcinoma neoplasias::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas::carcinoma hepatocelular [ENFERMEDADES] Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS] Organic Chemicals::Hydrocarbons::Hydrocarbons Cyclic::Hydrocarbons Aromatic::Benzene Derivatives::Phenylurea Compounds::Sorafenib [CHEMICALS AND DRUGS] Sorafenib Other subheadings::Other subheadings::/drug therapy [Other subheadings] Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores] Persones grans Medicaments antineoplàstics - Efectes secundaris Fetge - Càncer - Tractament Elderly patients compuestos orgánicos::hidrocarburos::hidrocarburos cíclicos::hidrocarburos aromáticos::derivados del benceno::compuestos de fenilurea::sorafenib [COMPUESTOS QUÍMICOS Y DROGAS] Neoplasms::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms::Carcinoma Hepatocellular [DISEASES] Oncology Persons::Age Groups::Adult::Aged [NAMED GROUPS] Other subheadings::Other subheadings::/adverse effects [Other subheadings] Overall survival Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS] Safety personas::Grupos de Edad::adulto::anciano [DENOMINACIONES DE GRUPOS] neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::adenocarcinoma::carcinoma hepatocelular [ENFERMEDADES] Outcome |
| Zdroj: | Scientia |
| Popis: | Elderly patients; Hepatocellular carcinoma; Sorafenib Pacientes ancianos; Carcinoma hepatocelular; Sorafenib Pacients grans; Carcinoma hepatocel·lular; Sorafenib Introduction: The first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There is little evidence of efficacy and tolerability in elderly patients under systemic treatment. The aims of this study were to characterize the profile of elderly patients treated with sorafenib, assess their survival and safety profile in order to extrapolate their eligibility for systemic treatment. Methods: Retrospective multicentre study of HCC patients aged ≥75 years old treated with sorafenib from January 2008 to December 2019. Demographic data, baseline characteristics, and variables related to HCC and sorafenib were recorded. Overall survival (OS) and safety were analyzed. Results: The study included 206 patients from 11 hospitals, median age 77.9 years; 71.4% men and 62.6% stage Barcelona Clinic Liver Cancer- C (BCLC-C). The main causes of cirrhosis were hepatitis C (60.7%) and alcohol (14.7%). Most patients (84.5%) started with sorafenib 800mg and 15.5% at lower dosage. Arterial hypertension (AHT) (74.2 vs 62.2%; standardized mean differences (STD): 26) and baseline ECOG-PS>0 (45.3 vs 34.7%; STD: 38.2) differed significantly between patients receiving low and full doses. Median OS was 15.4 months (18.2 in BCLC-B vs 13.6 in BCLC-C). OS was not modified by comorbidities, age or period with more expertise. Conclusions: Sorafenib appears to be safe in elderly patients with HCC. This is the first study to characterize the profile of elderly patients to be considered for systemic treatment. These findings could be used as the reference profile for elderly candidates for atezolizumab-bevacizumab. AS: Travel grants from Tillots, Ferring, Norgine, Alfasigma, Jansen, Abbvie. MC: None. ZV: None. SM-M: None. VS: Travel grants from Bayer. Consultancy LEO Pharma. MP: None. LC: None. RG: None. AG: None. BM: Consultancy: Bayer-Shering Pharma, Eisai-Merck. Conferences/lectures: Eisai, MSD, Roche. Research grant: Lab Viñas. Funding: BM is funded by grants PI18/00961 and PI21/00714 from Instituto de Salud Carlos III. DH. None. AC. None. SM. Conferences/lectures: Bayer. Travel grants: Bayer, and Eisai. MRo. None. MRe. Consultancy: Bayer-Shering Pharma, BMS, Roche, Ipsen, AstraZeneca, Lilly. BTG/Paid conferences: Bayer-Shering Pharma, BMS, Gilead, Lilly. Research Grants: Bayer-Shering Pharma, Ipsen. MV. Travel grants: Gilead, MSD, Bayer, Abvie. Conferences/lectures: MSD, Gilead, Abvie, Eisai. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|